centrifugation and frozen (Ϫ20°C) until analyzed. Times of drug injection and sampling were expressed in local time.
Ceftriaxone concentrations in serum were determined by a previously described microbiological assay (2) . Standard curves of ceftriaxone were prepared from pooled rat serum samples that were run simultaneously with test samples. The quantification limit was 1.17 g/ml. The correlation coefficient for the regression line of the standard solution was 0.997. The withinand between-day coefficients of variation were less than 10% in the range of observed concentrations (600 to 1.17 g/ml).
The serum ceftriaxone concentration-time curve for all groups was fitted to a one-compartment model using a nonlinear least-squares regression program (TOPFIT 2.0; Gustav Fischer, Jena, Germany). Pharmacokinetic parameters calculated were as follows: absorption (k abs ) and elimination (k el ) rate constants, absorption (t 1/2abs ) and elimination (t 1/2el ) halflives, area under the concentration-versus-time curve (AUC), total serum drug clearance (CL T ), volume of distribution (V), lag time (T lag ), peak serum concentration (C max ), and time to reach C max (T max ) (8) . Pharmacokinetic parameters were further analyzed by the cosinor method (18) for the presence of a 24-h (circadian) rhythm. This procedure is applicable to longitudinal biologic time series and consists of fitting a cosine curve of constant frequency to sequential data by the leastsquares statistical method. Estimated rhythmicity parameters follow: M, mesor (rhythm-adjusted mean); A, amplitude (distance between the mesor and the peak value of the cosine functions); and , acrophase (peak value of the fitted cosine function, with midnight [local time] the reference time). The corresponding equation model is Y ϭ (M ϩ A) ϫ cos(0.261t ϩ ). With this method, the goodness of fit of the cosine curve to the data is indicated by minimizing the sum of squares of the residuals from the analysis (probability of rhythm [PR] value). Rhythm detection is determined by the statistical significance of the amplitude, estimated by testing the null hypothesis that A ϭ 0 (no rhythm exists) by an F test. A PR value of Ն70 and P Յ 0.05 were considered indicative of rhythm. Relative amplitude was estimated as percent of the mesor (A/M ϫ 100). Figure 1 shows the mean concentration-versus-time curve of ceftriaxone in serum after it was administered intraperitoneally at 0400, 1000, 1600, and 2200 h. The pharmacokinetic param-eters for each group are presented in Table 1 . Cosinor analysis showed significant daily variations in CL T (PR ϭ 100, P ϭ 0.006). PR values for T lag, AUC, and T max indicated a good fit (98, 98, and 88%, respectively), but the P values were 0.14, 0.12, and 0.34, respectively. Mean estimated rhythm parameters (standard deviations given in parentheses) were as follows: for CL T , M ϭ 0.41 (0.0) ml/min, A ϭ Ϫ0.12 (0.0) ml/min, and acrophase at 22.08 h; for AUC, M ϭ 439.7 (10.2) g/ml · h, A ϭ 113.2 (14.5) g/ml · h, and acrophase at 9.77 h; for T lag , M ϭ 0.041 (0.004) h, A ϭ 0.03 (0.005) h, and acrophase at 3.05 h; and for T max , M ϭ 0.2 (0.01) h, A ϭ 0.05 (0.01) h, and acrophase at 6.11 h. Relative amplitude was higher for T lag (93%) and lower for AUC and T max (25%). Other calculated pharmacokinetic parameters, such as k abs , C max , k el , and V, did not exhibit significant rhythmic variations. Figure 2 shows the daily variations observed for CL T , T lag , AUC, and T max .
Several studies have reported temporal variations in the pharmacokinetics of antimicrobial drugs (1, 3, 13, 16, 26, (29) (30) (31) . Our results show that the total clearance of ceftriaxone varies rhythmically during the day, with its maximum during the dark (activity) period and its minimum during the light (rest) period in rats; however, it must be noted that as intravenous administration was not performed, bioavailability was not included in our CL T calculation. As ceftriaxone is eliminated by biliary and renal excretion in the rat (9, 15) , this temporal variation can be attributed, at least partially, to circadian changes in different steps of the kinetic process, such as the biliary and renal functions. Basal bile flow has been reported to exhibit a circadian rhythm with higher values during the active phase of rats (10) . The biliar anion carrier system shows its maximum transport capacity during activity (rather than rest) in rats (16, 30) . Urinary water, protein and glycosaminoglycan excretions, and glomerular filtration rate (GFR) and renal plasma flow (RPF) show a circadian rhythmicity in rats, with markedly increased values observed during the dark phase in the animals (6, 21, 22) . Similar findings were reported for urinary electrolyte (K, P, Mg, Ca, and Na) excretion (21, 25) . Cardiac output changes as a function of the diurnal activity FIG. 1. Ceftriaxone concentrations obtained in serum after the intraperitoneal administration (100 mg/kg) to female Sprague-Dawley rats at 0400, 1000, 1600, and 2200 h. Each sampling point represents the mean Ϯ standard deviation (error bar) of data for four to six rats. TABLE 1. Pharmacokinetic parameters calculated after the intraperitoneal administration of ceftriaxone (100 mg/kg) to female Sprague-Dawley rats at 0400, 1000, 1600, and 2200 h and feeding patterns in rats, and renal and biliar blood flow are higher during the activity phase in the rat (7). As GFR, RPF, and renal and biliary excretion follow the same circadian pattern, these factors could be responsible for the time-dependent variation of ceftriaxone clearance. During the 24 h, CL T acrophase in the dark phase was 180°o ut of phase with that of AUC, while T max and T lag profiles were very similar, thus confirming the relationship between these two parameters. No rhythm was seen for k el , as this parameter depends on CL T and V, and the latter did not exhibit circadian rhythmicity. Circadian changes in the distribution of the cardiac output may account for the acrophase of T max and T lag observed during the end of the dark period, indicating slower absorption at this time. A period of transitory locomotion activity and sleeping behavior with no feeding activity occurs at the beginning of the light phase and may also exist during the end of the dark phase in the rat. During this period, cardiac output is low and skeletal muscle receives the greatest proportion of this output, while visceral blood flow is low (7) . Thus, absorption during this transition may be slower than in other times of day.
Our data are in good agreement with the data of other researchers. In humans, the amount of ciprofloxacin eliminated in urine was greater when the drug was administered at 1000 h than when it was given at 2200 h (26) . In rats, when tobramycin was administered at 0200 h (dark period), the CL T was significantly higher and AUC was lower than the values when tobramycin was given at 1400 h (light period) (13) . A population pharmacokinetic study of amikacin in humans showed higher values for k el in the morning than in the evening. Ampicillin biliar and renal clearances were significantly higher during the active cycle of rats than during the sleep cycle (16, 30) .
Experimental animal models have shown that for antibiotics such as ␤-lactams that have concentration-independent killing effects in vitro, the time that the antibiotic concentration remains greater than the MIC (TϾMIC) is the most important factor for determining the in vivo efficacy (11, 14, 27) . Therefore, daily variations in pharmacokinetics may account for impairment in the chemotherapeutic effects. Our results demonstrate that the disposition of ceftriaxone in rats exhibits significant daily changes that could be attributed mainly to enhanced excretion during the active period; thus, TϾMIC may be shorter when ceftriaxone is administered during the active phase. This is of great importance when bacteria with low susceptibility are involved in the infectious processes, particularly as ceftriaxone concentrations are lower in tissues than in blood. It can be concluded that the time of administration for ceftriaxone may affect therapeutic efficacy in current oncedaily dosing schedules. 
